Nisa Investment Advisors
ARQT icon

Nisa Investment Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

Nisa Investment Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.8K Buy
1,633
+404
+33% +$9.41K ﹤0.01% 1912
2026
Q1 		$29K Buy
1,229
+3
+0.2% +$77 ﹤0.01% 1884
2025
Q4 		$35.6K Sell
1,226
-153
-11% -$3.92K ﹤0.01% 1729
2025
Q3 		$26K Hold
1,379
– – ﹤0.01% 1870
2025
Q2 		$19.3K Sell
1,379
-18
-1% -$252 ﹤0.01% 1954
2025
Q1 		$21.8K Buy
1,397
+28
+2% +$394 ﹤0.01% 1835
2024
Q4 		$19.1K Buy
1,369
+96
+8% +$1.05K ﹤0.01% 1949
2024
Q3 		$11.8K Buy
1,273
+205
+19% +$2.02K ﹤0.01% 2064
2024
Q2 		$9.93K Buy
1,068
+943
+754% +$8.53K ﹤0.01% 2155
2024
Q1 		$1.24K Buy
+125
New +$933 ﹤0.01% 2324
2023
Q3 		– Sell
-46
Closed -$438 – 2775
2023
Q2 		$438 Buy
+46
New +$511 ﹤0.01% 2585
2023
Q1 		– Sell
-13,900
Closed -$206K – 2523
2022
Q4 		$206K Sell
13,900
-35
-0.3% -$611 ﹤0.01% 1364
2022
Q3 		$266K Buy
13,935
+35
+0.3% +$793 ﹤0.01% 1201
2022
Q2 		$296K Hold
13,900
– – ﹤0.01% 1202
2022
Q1 		$268K Buy
+13,900
New +$235K ﹤0.01% 1265

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Nisa Investment Advisors's ARQT Position: Q2 2026 in Review

Nisa Investment Advisors increased its Arcutis Biotherapeutics (ARQT) stake by 33% in Q2 2026, buying an estimated $9.41K and bringing the position to 1,633 shares worth $42.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1912.

Nisa Investment Advisors first reported a position in ARQT in Q1 2022 and has held it in 15 quarters since. The position peaked at $296K in Q2 2022. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Nisa Investment Advisors held 1,633 shares of Arcutis Biotherapeutics worth $42.8K as of Q2 2026.
  • Nisa Investment Advisors bought 404 Arcutis Biotherapeutics shares in Q2 2026, an estimated $9.41K.
  • Arcutis Biotherapeutics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #1912 holding.
  • Nisa Investment Advisors first reported a position in Arcutis Biotherapeutics in Q1 2022 and has held it in 15 quarters since.
  • Nisa Investment Advisors's Arcutis Biotherapeutics position peaked at $296K in Q2 2022.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.